NANJING, China, Aug. 29, 2023 /PRNewswire/ — Brace for Impact: InxMed, a beacon of innovation in the biotech arena, is making waves yet again. Focused on conquering drug resistance in formidable solid tumors, the clinical-stage powerhouse has proudly unveiled its latest triumph. Meet OMTX705, a pioneering ADC that has just secured the coveted green light – an IND (Investigational New Drug) approval from China’s National Medical Products Administration (NMPA). The stage is set for a revolution in hard-to-treat cancers.
Unveiling the Future of Cancer Treatment: Introducing OMTX705, a Trailblazing Antibody-Drug Conjugate (ADC) by InxMed
Prepare to be amazed by OMTX705, a revolutionary antibody-drug conjugate (ADC) poised to transform cancer treatment. Its target? Fibroblast-activating protein α (FAPα), a potent player expressed in cancer-associated fibroblasts (CAF) enveloping tumors and their intricate microenvironment. In a symphony of breakthrough research, InxMed and its collaborators have spotlighted the pivotal role FAP-expressing CAFs play in drug resistance – a revelation that could change the game for hard-to-treat cancers.
The brilliance of OMTX705 shines even brighter in its focus on Chinese populations, zeroing in on high-incidence cancers like gastric and esophagus cancers. The collaboration with Oncomatryx, a fellow innovator in the realm of tumor microenvironment targeting, sets the stage for preclinical and clinical research that’s set to redefine possibilities. With the power of InxMed behind it, OMTX705 has Asia in its sights.
But this isn’t InxMed’s first stride into the realm of cutting-edge oncology. Since 2019, they’ve been pioneers in crafting novel ADC drugs for the toughest solid tumors. Their work with IN10018 (Ifebemtinib), a potent focal adhesion kinase (FAK) inhibitor, has shown immense promise in animal models. With their eyes on the horizon, InxMed is trailblazing through synergistic pipelines and partnerships, maximizing the potential of every breakthrough.
The stage is set, the mission clear – InxMed is rewriting the rules of cancer therapy, one innovative step at a time.
Trailblazing the Future of Cancer Solutions: Meet InxMed, the Visionary Clinical-Stage Biotech Pioneer of 2018.
Stepping into the spotlight at the end of 2018, InxMed emerged as the embodiment of innovation. With a steadfast focus on the intricate battlefields of stroma microenvironments, solid tumor resilience, and metastasis, this powerhouse is rewriting the rulebook of cancer treatment. Their pièce de résistance? Pioneering new frontiers in anti PD-1/PD-L1 treatment drug resistance.
Picture a symphony of breakthroughs orchestrated by InxMed’s dedication to bridging the gap between science and clinical solutions. Anchored in a profound understanding of disease biology, they’re not just crafting treatments – they’re sculpting revolutions. With a resolute vision, InxMed’s journey is a global tapestry woven with clinical teams in Nanjing, Shanghai, and Beijing, echoed by strategic hubs across the United States, Canada, and Australia. This isn’t just research; it’s a symposium of transformation.
Fueling their ascent are successful rounds of financing, a testament to their promise, with over 100 million US dollars invested. Enter IN10018, a beacon of their innovation, a highly selective oral focal adhesion kinase (FAK) inhibitor. It’s no surprise that this visionary drug earned Fast-track Designation from the U.S. Food and Drug Administration and Breakthrough Therapy Designation from China’s National Medical Products Administration. The grand stage is set, with pivotal clinical trials shaping the landscape of market approval – a scene where miracles come to life.
InxMed’s mission is more than a journey; it’s a symphony of global collaboration, innovation, and transformation, all in the name of shaping the future of cancer care.